Novo Nordisk to invest $2.3 billion in French facility to address GLP-1 drug shortage
.png)
Manufacturing for the diabetes and weight-loss drugs Ozempic and Wegovy is expected to increase with a billion-dollar investment Novo Nordisk production site located in Chartres, France.
Danish pharmaceutical giant Novo Nordisk announces a $2.3 billion investment into its Chartres, France manufacturing site to boost production of weight-loss and diabetes drugs such as Wegovy and Ozempic, among others.
A growing supply crisis of semaglutide drug products has European healthcare systems worried. The off-label use of Ozempic as an obesity treatment. Ozempic in particular has faced supply shortages in Europe because of its popularity in weight-loss treatment, while Wegovy is not yet widely available in Europe. Some nations are considering bans on off-label prescriptions for Ozempic; Germany has considered banning exports of the drug, while Belgium banned non-diabetes related prescriptions of Ozempic. Novo Nordisk itself has introduced rations for Ozempic starter kits in response to increased demand for weight-loss treatments. Earlier in November 2023, Novo Nordisk announced an increase in investment to $6 billion for production within Denmark.
Estimate analysis of the obesity drug market shows a potential worth of $100 billion by 2030. The investment into the French manufacturing plant will also serve as a boost for France’s economy as it faces a global economic slowdown. During the ‘Choose France’ summit earlier in the year, the office of French President Emmanuel Macron announced they had convinced Novo Nordisk CEO Lars Fruergaard Jorgensen to invest in the French manufacturing site. However, Novo Nordisk has yet to comment on this.
The investment will significantly increase the several types of manufacturing required for the production of GLP-1 drug class, with specialist operations for the filling of injection pens with the API semaglutide. Assembly and packaging operations of the injection pens will also be increased.
Source: Novo Nordisk invests $2.3 billion in France to boost obesity drug production [Accessed November 29, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invests-23-mln-france-boost-output-2023-11-23/
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance